Deciphering RNA to Predict if a Patient Will Respond to a Targeted Drug

LAURA ELIZABETH LANSDOWNE | January 21, 2019

article image
Ineffective drugs have a profound impact on patients. First of all, the patient could be taking a medication that not only doesn't make them feel better but could also result in unwanted adverse effects. Establishing a way to ensure patients are prescribed optimal treatment from day one while avoiding adverse effects and the billions of dollars that payers and patients waste each year on ineffective treatments is key to combating this dilemma.

Spotlight

Shift Health Advisory, LLC

We bring deep operating company experience driving results across complex, multi-stakeholder ecosystems - direct to consumer (DTC) and with an array of partners including health insurers, health systems, health technology, analytics and digital health companies.

OTHER ARTICLES

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | April 10, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

The Future of Pharma Beyond Blockbusters

Article | April 10, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

What to Watch in 2020: Non-Specialty Drugs

Article | April 10, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Spotlight

Shift Health Advisory, LLC

We bring deep operating company experience driving results across complex, multi-stakeholder ecosystems - direct to consumer (DTC) and with an array of partners including health insurers, health systems, health technology, analytics and digital health companies.

Events